4 assets in Botryoid Rhabdomyosarcoma

Therapeutic assets addressing Botryoid Rhabdomyosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Botryoid Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Dactinomycin Botryoid Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vincristine Sulfate Botryoid Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)
Vinorelbine Ditartrate Botryoid Rhabdomyosarcoma	Children's Oncology Group	P3	B (60)